CTCX 📈 Carmell Therapeutics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
CTCX: Skin Care, Hair Care, Men's Grooming Products, Plasma-Based Plastics
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania. Web URL: https://www.carmellcosmetics.com
Additional Sources for CTCX Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CTCX Stock Overview
Market Cap in USD | 7m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2023-07-17 |
CTCX Stock Ratings
Growth 5y | -84.3% |
Fundamental | 7.95% |
Dividend | - |
Rel. Strength Industry | -6952 |
Analysts | - |
Fair Price Momentum | 0.32 USD |
Fair Price DCF | - |
CTCX Dividends
No Dividends PaidCTCX Growth Ratios
Growth Correlation 3m | -34.9% |
Growth Correlation 12m | -96.1% |
Growth Correlation 5y | -68.7% |
CAGR 5y | -61.45% |
CAGR/Mean DD 5y | -1.68 |
Sharpe Ratio 12m | -0.27 |
Alpha | -102.97 |
Beta | 0.44 |
Volatility | 646.08% |
Current Volume | 482.6k |
Average Volume 20d | 20019.4k |
What is the price of CTCX stocks?
As of January 10, 2025, the stock is trading at USD 0.42 with a total of 482,570 shares traded.
Over the past week, the price has changed by -39.30%, over one month by +51.06%, over three months by -2.05% and over the past year by -87.27%.
As of January 10, 2025, the stock is trading at USD 0.42 with a total of 482,570 shares traded.
Over the past week, the price has changed by -39.30%, over one month by +51.06%, over three months by -2.05% and over the past year by -87.27%.
Is Carmell Therapeutics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Carmell Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.95 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTCX as of January 2025 is 0.32. This means that CTCX is currently overvalued and has a potential downside of -23.81%.
Neither. Based on ValueRay Fundamental Analyses, Carmell Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.95 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTCX as of January 2025 is 0.32. This means that CTCX is currently overvalued and has a potential downside of -23.81%.
Is CTCX a buy, sell or hold?
Carmell Therapeutics has no consensus analysts rating.
Carmell Therapeutics has no consensus analysts rating.
What are the forecast for CTCX stock price target?
According to ValueRays Forecast Model, CTCX Carmell Therapeutics will be worth about 0.3 in January 2026. The stock is currently trading at 0.42. This means that the stock has a potential downside of -19.05%.
According to ValueRays Forecast Model, CTCX Carmell Therapeutics will be worth about 0.3 in January 2026. The stock is currently trading at 0.42. This means that the stock has a potential downside of -19.05%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 0.3 | -19% |